Follow The Leader: The cost of listening to only 1 guideline

<style>
  * {
    margin: 0;
    padding: 0;
    box-sizing: border-box;
  }

  body {
    font-family: Arial, sans-serif;
    font-size: 17px;
    line-height: 1.8;
    color: #333;
    background-color: #F0F7F7;
    padding: 20px;
  }

  .ca-container {
    max-width: 100%;
    margin: 0 auto;
    background-color: white;
    padding: 40px;
    border-radius: 4px;
  }

  .ca-title {
    font-family: Georgia, serif;
    font-size: 30px;
    color: #1B3A5C;
    text-align: center;
    margin-bottom: 30px;
    line-height: 1.3;
  }

  .ca-disclaimer-box {
    background-color: #f5f5f5;
    border-left: 4px solid #2E8B8B;
    padding: 15px;
    margin-bottom: 30px;
    font-style: italic;
    font-size: 15px;
    line-height: 1.6;
  }

  h2 {
    font-family: Georgia, serif;
    font-size: 24px;
    color: #1B3A5C;
    margin-top: 35px;
    margin-bottom: 15px;
    padding-bottom: 10px;
    border-bottom: 2px solid #1B3A5C;
  }

  h3 {
    font-family: Georgia, serif;
    font-size: 19px;
    color: #2E8B8B;
    margin-top: 20px;
    margin-bottom: 10px;
  }

  p {
    margin-bottom: 15px;
    line-height: 1.8;
  }

  ul {
    margin-left: 20px;
    margin-bottom: 15px;
  }

  li {
    margin-bottom: 8px;
    list-style-type: none;
    padding-left: 25px;
    position: relative;
  }

  li:before {
    content: "■";
    color: #2E8B8B;
    position: absolute;
    left: 0;
  }

  .ca-callout {
    border-left: 4px solid #2E8B8B;
    background-color: #F0F7F7;
    padding: 15px;
    margin: 20px 0;
    font-weight: normal;
  }

  .ca-callout strong {
    color: #1B3A5C;
  }

  .ca-checklist {
    background-color: #F0F7F7;
    border: 1px solid #2E8B8B;
    border-radius: 4px;
    padding: 20px;
    margin: 20px 0;
  }

  .ca-checklist-item {
    margin-bottom: 12px;
    display: flex;
    align-items: flex-start;
  }

  .ca-checkbox {
    width: 18px;
    height: 18px;
    border: 2px solid #2E8B8B;
    border-radius: 2px;
    margin-right: 12px;
    margin-top: 2px;
    flex-shrink: 0;
    background-color: white;
  }

  .ca-summary-box {
    border: 2px solid #2E8B8B;
    border-radius: 4px;
    padding: 20px;
    background-color: #F0F7F7;
    margin: 30px 0;
  }

  .ca-summary-box h3 {
    color: #1B3A5C;
    margin-top: 0;
  }

  .ca-tagline {
    text-align: center;
    font-style: italic;
    color: #2E8B8B;
    margin: 25px 0;
    font-size: 17px;
  }

  .ca-closing-disclaimer {
    background-color: #f5f5f5;
    border-left: 4px solid #2E8B8B;
    padding: 15px;
    margin-top: 30px;
    font-size: 15px;
    line-height: 1.6;
  }

  a {
    color: #2E8B8B;
    text-decoration: underline;
  }

  a:hover {
    color: #1B3A5C;
  }

  table {
    width: 100%;
    border-collapse: collapse;
    margin: 20px 0;
  }

  th {
    background-color: #2E8B8B;
    color: white;
    padding: 12px;
    text-align: left;
    font-weight: bold;
  }

  td {
    border-bottom: 1px solid #ddd;
    padding: 10px 12px;
  }

  tr:nth-child(even) {
    background-color: #F0F7F7;
  }
  .fl-foot-stomper { background: linear-gradient(135deg, #1B3A5C 0%, #2E8B8B 100%); color: #fff; padding: 20px 25px; margin: 25px 0; border-radius: 8px; border-left: 6px solid #FFB300; }
  .fl-foot-stomper-title { font-family: Georgia, serif; font-size: 18px; font-weight: bold; margin-bottom: 8px; color: #FFB300; }
  .fl-foot-stomper-text { font-family: Arial, sans-serif; font-size: 16px; line-height: 1.7; }
</style>

<div class="ca-container">
  <div class="ca-disclaimer-box">
    <strong>Medical Disclaimer:</strong> This article is for educational purposes only and should not replace professional medical advice. Always consult with a qualified healthcare provider regarding diagnosis, treatment options, and personal health decisions. If you experience chest pain, shortness of breath, or other emergency symptoms, seek immediate medical attention.
  </div>

  <!-- CASE PRESENTATION -->
  <h2 id="deep-dive">Case Presentation</h2>

  <p><strong>Setting:</strong> <span class="ca-gterm" data-term="American College of Cardiology">American College of Cardiology</span> (ACC) 62nd Annual Scientific Session, San Francisco, CA | March 9-11, 2013</p>

  <p>A packed crowd, spilling out into the foyer of the lecture hall, awaited the much anticipated release of the new 2013 ACC/<span class="ca-gterm" data-term="American Heart Association">AHA</span> Blood <span class="ca-gterm" data-term="Cholesterol">Cholesterol</span> <span class="ca-gterm" data-term="Cardiovascular Risk Guidelines">Guidelines</span>. They weren't quite ready and they were not released at that time, so a Q&A session with the Guideline writing committee members was held instead, offering a hint of what we might expect from these guidelines.</p>

  <p>Based on what they had already heard, an audience participant asked one of the Guideline writers what they would do in the following situation:</p>

  <div class="ca-callout">
    <p><strong>The Scenario:</strong> A patient who had had an <span class="ca-gterm" data-term="Atherosclerotic Cardiovascular Disease">ASCVD</span> event who was placed on a maximum high intensity <span class="ca-gterm" data-term="Statin">statin</span>, like Atorvastatin 80 mg daily, but achieved an on-treatment <span class="ca-gterm" data-term="LDL Cholesterol">LDL-C</span> of just over 100 mg/dL (previous guidelines called for LDL < 70 mg/dL). What next?</p>
    <p><strong>Guideline writer's reply:</strong> "I think you're done."</p>
  </div>

  <p>This was a stark departure from prior and existing guidelines and in this particular scenario, offered a treatment strategy that was inferior to the current standard of care, leaving countless high risk patients at risk for undertreatment and exposing them unnecessarily to excess <span class="ca-gterm" data-term="Residual Risk">residual risk</span>.</p>

  <p>It seemed to promote the outdated "<span class="ca-gterm" data-term="Fire and Forget">fire and forget</span>" strategy (enjoyed by the lazy practitioner), where all you needed to do was place your high risk patients on a "high intensity statin" and call it a day. "Poof", done. Never check a <span class="ca-gterm" data-term="Lipid Panel">lipid panel</span> again. Obviously, that's not exactly what was said, nor intended by the Guideline Committee, but that's how it was received by many.</p>

  <!-- FLYING UNDER THE RADAR -->
  <h2>Flying Under the Radar</h2>

  <p>"But my doctor is following the guidelines - is it possible that I am being undertreated?" Yes, it is. Providers are human and they often "follow the leader." When it comes to cardiovascular guidelines, the leader is often the American College of Cardiology and the American Heart Association (ACC/AHA).</p>

  <p>However guidelines are just that - guidelines. They don't always apply to everyone (for instance, certain ethnic groups). They don't always apply to every situation. There are many of them out there and they're not always created equal. And yes, as well respected as these organizations are, sometimes they get it wrong. That was the case with the 2013 ACC/AHA Blood Cholesterol Guidelines. They were well intentioned and they had their reasons, but it was a swing and a miss and set the lipid community back several years.</p>

  <div class="ca-callout"><strong>Fortunately, medicine is a team sport.</strong> Other stakeholders picked up the baton, ran with it and tried to make up for lost ground.</div>

  <!-- CARDIOADVOCATE CHECKLIST -->
  <h2>CardioAdvocate Checklist</h2>

  <p><strong>For Patients and Providers</strong></p>

  <div class="ca-checklist">
    <div style="margin-bottom: 20px; font-weight: bold; color: #1B3A5C;">Know Your Baseline Risk</div>

    <div class="ca-checklist-item">
      <div class="ca-checkbox"></div>
      <div>
        <strong>Identify your risk category:</strong>
        <ul style="margin-top: 8px; margin-left: 15px;">
          <li><strong>Highest Risk</strong> — <span class="ca-gterm" data-term="Secondary Prevention">Secondary prevention</span>: >20% ten year risk of ASCVD event, CAC >300, <span class="ca-gterm" data-term="Familial Hypercholesterolemia">Familial Hypercholesterolemia</span>, Elevated <span class="ca-gterm" data-term="Lipoprotein(a)">Lp(a)</span> >325 nmol/L, High <span class="ca-gterm" data-term="Lifetime Risk">lifetime risk</span></li>
          <li><strong>Use the <span class="ca-gterm" data-term="PREVENT-ASCVD">PREVENT-ASCVD</span> calculator (2026 update)</strong> for 10-year and 30-year risk estimation. This replaced the <span class="ca-gterm" data-term="Pooled Cohort Equations">Pooled Cohort Equations</span> in 2026. New risk tiers: Low (<3%), Borderline (3-<5%), Intermediate (5-<10%), High (≥10%)</li>
          <li><strong>Also use multiple additional risk calculators</strong> for cross-validation: Reynolds (includes family history and <span class="ca-gterm" data-term="High-Sensitivity C-Reactive Protein">hs CRP</span>), Framingham, and European HeartScore</li>
        </ul>
      </div>
    </div>

    <div class="ca-checklist-item">
      <div class="ca-checkbox"></div>
      <div><strong>Has your Lp(a) been checked?</strong> The 2026 ACC/AHA guidelines now recommend universal Lp(a) screening (Class I) for all adults at least once in a lifetime. Elevated Lp(a) is ≥125 nmol/L (≥50 mg/dL)</div>
    </div>

    <div class="ca-checklist-item">
      <div class="ca-checkbox"></div>
      <div><strong>Ask about your <span class="ca-gterm" data-term="ApoB">ApoB</span> level</strong> — The 2026 ACC/AHA guidelines now formally recommend (Class IIa) ApoB measurement for patients on <span class="ca-gterm" data-term="Lipid-Lowering Therapy">lipid-lowering therapy</span> with ASCVD, metabolic dysfunction, diabetes, or elevated <span class="ca-gterm" data-term="Triglycerides">triglycerides</span></div>
    </div>

    <div class="ca-checklist-item">
      <div class="ca-checkbox"></div>
      <div><strong>Consider multiple guidelines</strong> — Choose the guideline(s) most applicable to the individual being treated</div>
    </div>

    <div class="ca-checklist-item">
      <div class="ca-checkbox"></div>
      <div><strong>Consider Expert Opinion</strong> within the framework of a patient-centered discussion with your care team members. If in doubt, seek expert advice from a <span class="ca-gterm" data-term="Cardiometabolic">cardiometabolic</span> specialist or lipidologist</div>
    </div>
  </div>

  <h3>Recommended Resources</h3>
  <ul>
    <li><a href="https://professional.heart.org/en/guidelines-and-statements/prevent-calculator" target="_blank" rel="noopener">PREVENT-ASCVD Calculator (AHA)</a> — 10-year and 30-year risk estimation (2026)</li>
    <li><a href="https://shareddecisions.mayoclinic.org/statindecisionaid/" target="_blank" rel="noopener">Mayo Clinic Statin Choice Decision Aid</a> — Contains multiple risk calculators</li>
    <li><a href="https://www.learnyourlipids.com/find-a-clinician/" target="_blank" rel="noopener">LearnYourLipids</a> — Find a clinician specializing in lipid management</li>
  </ul>

  <h3>Expert Thought Leaders</h3>
  <ul>
    <li><a href="https://x.com/JohnKastelein" target="_blank" rel="noopener">John Kastelein (@JohnKastelein) on X</a></li>
    <li><a href="https://x.com/Drlipid" target="_blank" rel="noopener">Thomas Dayspring (@Drlipid) on X</a></li>
  </ul>

  <!-- DEEPER DIVE -->
  <h2>Deep Dive</h2>

  <h3>The 2013 ACC/AHA Blood Cholesterol Guidelines: An Interesting Story</h3>

  <p>The 2013 ACC/AHA Blood Cholesterol Guidelines were created under the strictest interpretation of "Evidence Based Medicine," allowing only for data obtained from Randomized Controlled Trials (<span class="ca-gterm" data-term="Randomized Controlled Trial">RCT</span>) and/or <span class="ca-gterm" data-term="Meta-Analysis">meta-analysis</span> of Randomized Controlled Trials in crafting recommendations. This painted them into a corner and effectively created a situation where they undermined existing guidelines and were forced to abandon any sort of lipid goal or target. Instead, they vehemently declared that clinical trials to date had only shown that a particular dose of statin had achieved the positive outcomes, rather than a particular LDL-C goal attained, for instance.</p>

  <h3>Historical Context: The Path to 2013</h3>

  <p>Since 1985 the National Cholesterol Education Program has been managed by the <span class="ca-gterm" data-term="National Heart, Lung, and Blood Institute">NHLBI</span>, a division of the <span class="ca-gterm" data-term="National Institutes of Health">NIH</span> and produced guidelines on cholesterol. The last guideline published was the Adult Treatment Panel III (NCEP ATPIII) in 2001 and updated in 2004 (ATP III Report on High Blood Cholesterol) to include an optional goal of LDL-C < 70 mg/dL for very high risk patients. Its 284 pages is a tour de force in how to write a guideline. It was chaired by Scott Grundy M.D., Ph.D., a legend in the field of atherosclerosis. The guideline reviewed and appropriately weighted the totality of available scientific evidence, providing useful and balanced recommendations. Within its text is an abundance of educational material to include the criteria for metabolic syndrome. It remains a great resource for anyone interested in understanding atherosclerosis.</p>

  <p>The next iteration of guidelines were nearly complete, when in 2013 the NHLBI decided to no longer participate in the publication of various cardiometabolic guidelines to include cholesterol, high blood pressure, obesity and nutrition, turning these duties over to various stakeholders such as the ACC/AHA for the cholesterol guidelines. The guidelines writers remained intact. In trying to adhere to the Institute of Medicine's "guidelines for writing evidence-based guidelines," which prioritized RCTs above all other sources of evidence, it decided to completely restrict the 2013 Blood Cholesterol Guidelines from anything but RCT data, rather than simply prioritizing it.</p>

  <div class="ca-callout"><strong>The Irony:</strong> The ACC/AHA's risk calculator, the so-called Pooled Cohort Equation (ASCVD Risk Estimator +), which was derived from and promoted by the guidelines, had never been evaluated in any sort of RCT.</div>

  <h3>Populations and Disparities: What About Other Ethnic Groups?</h3>

  <p>Many ethnic groups have published lipid guidelines or consensus statements more applicable to their risk, such as:</p>
  <ul>
    <li><a href="https://pubmed.ncbi.nlm.nih.gov/32089456/" target="_blank" rel="noopener">Lipid Association of India</a> — Proposed low-density <span class="ca-gterm" data-term="Lipoprotein">lipoprotein</span> cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on <span class="ca-gterm" data-term="PCSK9 Inhibitor">PCSK9 inhibitor</span> monoclonal antibodies</li>
    <li><a href="https://pubmed.ncbi.nlm.nih.gov/35024056/" target="_blank" rel="noopener">Asian Pacific Society of Cardiology</a> — Consensus Recommendations on Dyslipidaemia</li>
    <li><a href="https://www.healthquality.va.gov/guidelines/cd/lipids/index.asp" target="_blank" rel="noopener">Veterans Affairs/DOD Clinical Practice Guidelines</a> — The Management of Dyslipidemia for Cardiovascular Risk Reduction (2020)</li>
  </ul>

  <h3>The Challenge of Standardization: Lipid Goals by Risk Categories</h3>

  <p>Unfortunately, as is often the case in medicine when multiple stakeholders are involved, there is no standardization of nomenclature when it comes to defining and categorizing risk. We have attempted to break down some of the more popular guidelines and statements with their respective risk categories, definitions and related lipid goals and recommendations.</p>

  <h3>AACE/ACE Risk Categories</h3>

  <p><strong>Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of <span class="ca-gterm" data-term="Cardiovascular Disease">Cardiovascular Disease</span> Algorithm – 2020 Executive Summary</strong></p>

  <h4>Extreme Risk</h4>
  <p><strong>Risk Factors:</strong></p>
  <ul>
    <li>Progressive ASCVD including unstable <span class="ca-gterm" data-term="Angina">angina</span></li>
    <li>Established clinical ASCVD + diabetes or <span class="ca-gterm" data-term="Chronic Kidney Disease">CKD</span> ≥3 or HeFH</li>
    <li>History of premature ASCVD (<55y Male, <65y Female)</li>
  </ul>

  <p><strong>Treatment Goals:</strong></p>
  <ul>
    <li>LDL-C <55 mg/dL "and" ≥50% reduction from baseline</li>
    <li><span class="ca-gterm" data-term="Non-HDL Cholesterol">Non-HDL-C</span> <70 mg/dL</li>
    <li>ApoB <70 mg/dL</li>
    <li>TG <150 mg/dL</li>
  </ul>

  <div class="ca-callout"><strong>Important:</strong> For example, if your LDL-C is 72 mg/dL at baseline, the goal would be <36 mg/dL! It is not 54 mg/dL. Far too many clinicians mistakenly practice this way. It is more of a threshold to treat with high intensity (>50% reduction of LDL-C). That's a huge difference!</div>

  <h4>Very High Risk</h4>
  <p><strong>Risk Factors:</strong></p>
  <ul>
    <li>Established clinical ASCVD or recent hospitalization for <span class="ca-gterm" data-term="Acute Coronary Syndrome">ACS</span>, carotid or peripheral vascular disease, or 10 y risk >20%</li>
    <li>Diabetes w/ ≥1 <span class="ca-gterm" data-term="Risk Factor">risk factor</span></li>
    <li>CKD ≥3 w/ <span class="ca-gterm" data-term="Albuminuria">albuminuria</span></li>
    <li>HeFH</li>
  </ul>

  <p><strong>Treatment Goals:</strong></p>
  <ul>
    <li>LDL-C <70 mg/dL "and" ≥50% reduction from baseline</li>
    <li>Non-<span class="ca-gterm" data-term="HDL Cholesterol">HDL-C</span> <100 mg/dL</li>
    <li>ApoB <80 mg/dL</li>
    <li>TG <150 mg/dL</li>
  </ul>

  <h4>High Risk</h4>
  <p><strong>Risk Factors:</strong></p>
  <ul>
    <li>≥2 risk factors & 10 y risk >10-20%</li>
    <li>Diabetes or CKD ≥3 & no other risk factors</li>
    <li>≥3 & no other risk factors</li>
  </ul>

  <p><strong>Treatment Goals:</strong></p>
  <ul>
    <li>LDL-C <70 mg/dL "and" ≥50% reduction from baseline</li>
    <li>Non-HDL-C <100 mg/dL</li>
    <li>ApoB <80 mg/dL</li>
    <li>TG <150 mg/dL</li>
  </ul>

  <h4>Moderate Risk</h4>
  <p><strong>Risk Factors:</strong></p>
  <ul>
    <li><2 risk factors & 10 y risk <10%</li>
  </ul>

  <p><strong>Treatment Goals:</strong></p>
  <ul>
    <li>LDL-C <100 mg/dL</li>
    <li>Non-HDL-C <130 mg/dL</li>
    <li>ApoB <90 mg/dL</li>
    <li>TG <150 mg/dL</li>
  </ul>

  <h4>Low Risk</h4>
  <p><strong>Risk Factors:</strong></p>
  <ul>
    <li>No risk factors</li>
  </ul>

  <p><strong>Treatment Goals:</strong></p>
  <ul>
    <li>LDL-C <130 mg/dL</li>
    <li>Non-HDL-C <160 mg/dL</li>
    <li>ApoB - not recommended</li>
    <li>TG <150 mg/dL</li>
  </ul>

  <h3>ESC/EAS Risk Categories</h3>

  <p><strong>2019 <span class="ca-gterm" data-term="European Society of Cardiology">ESC</span>/<span class="ca-gterm" data-term="European Atherosclerosis Society">EAS</span> Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk</strong></p>

  <h4>Very High Risk</h4>
  <p><strong>Risk Factors:</strong></p>
  <ul>
    <li>Recurrent ASCVD events (more than 1)</li>
    <li>Extensive atherosclerotic cardiovascular disease</li>
    <li>Higher global cardiovascular risk scores</li>
  </ul>

  <p><strong>Lipid Goals (Primary or Secondary Prevention):</strong></p>
  <ul>
    <li>LDL-C <55 mg/dL "and" ≥50% reduction from "baseline"</li>
    <li>LDL-C <40 mg/dL — Patients with ASCVD with another vascular event within 2 years (not necessarily the same type of event)</li>
    <li>Non-HDL-C <85 mg/dL</li>
    <li>Apolipoprotein B (ApoB) <65 mg/dL</li>
  </ul>

  <div class="ca-callout"><strong>Note on LDL-lowering:</strong> ESC/EAS says "LDL-lowering therapy," not necessarily "statin" therapy. The benefits derived from "high intensity statin" are dependent on the achieved LDL-C levels in individual trial participants. Notice they also say "LDL-lowering," not necessarily "LDL-C" — ApoB and <span class="ca-gterm" data-term="LDL Particles">LDL-P</span> are other acceptable biomarkers.</div>

  <h4>High Risk</h4>
  <p><strong>Risk Factors:</strong></p>
  <ul>
    <li>Markedly elevated single risk factor (LDL-C ≥190 mg/dL - severe hypercholesterolemia including FH; BP ≥180/110 mmHg)</li>
    <li>Familial Hypercholesterolemia (FH) without any additional risk factors</li>
    <li>Moderate CKD (Stage 3: <span class="ca-gterm" data-term="eGFR">eGFR</span> 30-59 mL/min/1.73 m²)</li>
    <li>DM without target damage</li>
    <li>DM ≥10 years or with another risk factor</li>
    <li>European HeartScore ≥5% and <10% 10 year risk of fatal CVD</li>
  </ul>

  <p><strong>Lipid Goals:</strong></p>
  <ul>
    <li>LDL-C <70 mg/dL "and" ≥50% reduction from "baseline"</li>
    <li>Non-HDL-C <100 mg/dL</li>
    <li>ApoB <80 mg/dL</li>
  </ul>

  <h4>Moderate Risk</h4>
  <p><strong>Risk Factors:</strong></p>
  <ul>
    <li>Young patients (T1DM <35 years, T2DM <50 years) with DM <10 years, without other risk factors</li>
    <li>European HeartScore ≥1% and <5% 10 year risk of fatal CVD</li>
  </ul>

  <p><strong>Lipid Goals:</strong></p>
  <ul>
    <li>LDL-C <100 mg/dL</li>
  </ul>

  <h4>Low Risk</h4>
  <p><strong>Risk Factors:</strong></p>
  <ul>
    <li>European HeartScore <1% 10 year risk of fatal CVD</li>
  </ul>

  <p><strong>Lipid Goals:</strong></p>
  <ul>
    <li>LDL-C <116 mg/dL</li>
  </ul>

  <h4>All Patients</h4>
  <p><strong>Consider:</strong></p>
  <ul>
    <li><strong>Lipoprotein a (Lp(a)):</strong> Considered at least once in every adult's lifetime to identify those with very high inherited Lp(a) levels >180 mg/dL (430 nmol/L). Considered in those with family history of premature CVD. Considered for reclassification of risk in borderline cases.</li>
    <li><strong>Triglycerides:</strong> TG <150 mg/dL indicates lower risk; TG >150 mg/dL, look for other risk factors</li>
    <li><strong>Diabetes:</strong> <span class="ca-gterm" data-term="Hemoglobin A1c">A1C</span> <7%</li>
  </ul>

  <h3>2014 National Lipid Association Management of Dyslipidemia Guidelines</h3>

  <h4>Very High Risk</h4>
  <p><strong>Risk Factors:</strong></p>
  <ul>
    <li>ASCVD</li>
    <li>DM - Type 1 or 2 with ≥2 other major ASCVD risk factors or end organ damage (microalbuminuria ≥30 mg/g, CKD, retinopathy)</li>
  </ul>

  <p><strong>Lipid Goals:</strong></p>
  <ul>
    <li>LDL-C <70 mg/dL and >50% reduction from baseline</li>
    <li>Non-HDL <100 mg/dL</li>
    <li>ApoB <80 mg/dL</li>
  </ul>

  <h4>High Risk</h4>
  <p><strong>Risk Factors:</strong></p>
  <ul>
    <li>LDL-C ≥190 mg/dL - severe hypercholesterolemia, including FH</li>
    <li>CKD ≥Stage 3B</li>
    <li>DM with 0-1 other major ASCVD risk factors</li>
  </ul>

  <p><strong>Lipid Goals (High, Moderate, Low Risk - <span class="ca-gterm" data-term="Primary Prevention">Primary Prevention</span>):</strong></p>
  <ul>
    <li>LDL-C <100 mg/dL</li>
    <li>Non-HDL <130 mg/dL</li>
    <li>ApoB <90 mg/dL</li>
  </ul>

  <h3>2018 AHA/ACC Guidelines</h3>

  <p><strong>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/<span class="ca-gterm" data-term="American Diabetes Association">ADA</span>/AGS/APhA/<span class="ca-gterm" data-term="American Society of Preventive Cardiology">ASPC</span>/<span class="ca-gterm" data-term="National Lipid Association">NLA</span>/PCNA Guideline on the Management of Blood Cholesterol</strong></p>

  <p>The AHA/ACC Cholesterol guidelines are best summed up with their recommendations regarding secondary prevention (ASCVD) and primary prevention. These guidelines represent a more conservative approach compared to the ESC/EAS recommendations.</p>

  <h3>Expert Opinion: Advanced Atherosclerosis</h3>

  <p>Beyond published guidelines, expert consensus statements offer additional insight:</p>

  <p><strong>Advanced <span class="ca-gterm" data-term="Atherosclerosis">atherosclerosis</span>:</strong></p>
  <ul>
    <li>LDL-C range between 20-40 mg/dL</li>
    <li>Based upon PCSK9i trials: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1615664" target="_blank" rel="noopener">FOURIER</a>, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1801174" target="_blank" rel="noopener">ODYSSEY</a>, <a href="https://jamanetwork.com/journals/jama/fullarticle/2584184" target="_blank" rel="noopener">GLAGOV</a></li>
    <li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9482082/" target="_blank" rel="noopener">Expert Opinion White Paper:</a> "There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision"</li>
    <li>A patient centered discussion may be had to discuss safety, efficacy and cost ratios</li>
  </ul>

  <h3>Other Notable Guidelines</h3>

  <ul>
    <li><a href="https://onlinecjc.ca/article/S0828-282X(21)00165-3/fulltext" target="_blank" rel="noopener">Canadian Cardiovascular Society: 2021 Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults</a></li>
  </ul>

  <h3>So Which Guidelines Do I Follow?</h3>

  <p><strong>In our opinion, that is up to the joint decision making of the patient and their care team.</strong></p>

  <p>There are numerous Cholesterol guidelines published by various organizations and medical societies around the globe. Some are more conservative than others. Some are more popular than others and get more attention. That doesn't always mean they are the most applicable to each unique patient with their own unique characteristics and circumstances.</p>

  <p>Our mission at CardioAdvocate.com is to eradicate atherosclerotic cardiovascular disease in everyone. We wish to make published resources and expert recommendations more available, thereby facilitating a more informed personalized discussion.</p>

  <p>In our highest risk patients, such as The Repeat Offender (The Heart Attack Survivor) we tend to align ourselves with the more aggressive lipid lowering recommendations, to include expert consensus opinion, rather than the more conservative recommendations of others, despite their popularity.</p>

  <div class="ca-callout"><strong>We agree with the following statement when it comes to our highest risk patients:</strong>
    <p style="margin-top: 10px;">"LDL-C levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients" - 2019 Joint ESC/EAS Dyslipidemia Guidelines</p>
    <p style="margin-top: 10px;">Put another way by Dr. John Kastelein at the ESC meeting in 2019: "LDL-C is a toxic agent that in principle needs eradication, but in practice needs early, long-term and aggressive lowering"</p>
  </div>

  <h3 id="conservative-aggressive">Conservative vs. Aggressive Approaches</h3>

  <p>By way of comparison, the more conservative 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol calls for a more conservative LDL-C threshold of 70 mg/dL for the addition of non-statins to maximally tolerated statins. It also calls for multiple major ASCVD events to occur or to have had a major ACVD event combined with multiple risk factors before the most aggressive action is taken.</p>

  <div class="ca-callout"><strong>In our view:</strong> Simply having any major ASCVD event is plenty and requires the most aggressive and urgent action ASAP!</div>

  <h3 id="esc-eas-2025">2025 ESC/EAS Focused Update — Breaking the Sisyphean Cycle?</h3>

  <p>In January 2026, Kausik Ray and Florian Kronenberg published a commentary in Atherosclerosis titled "Seventeen Years to Change Practice." The title alone says everything. Despite decades of evidence, it takes on average 17 years for medical guidelines to reach routine clinical care. The 2025 ESC/EAS Focused Update on dyslipidaemia management aims to break this cycle.</p>

  <h4>Key Shifts in the 2025 ESC/EAS Focused Update:</h4>

  <ul>
    <li><strong>Risk Assessment Modernized:</strong> SCORE2 and SCORE2-OP now factor in both fatal and non-fatal events and extend risk prediction up to age 89. Critically, this corrects years of underestimating risk in women and younger individuals.</li>

    <li><strong>Expanded Lipid-Lowering Toolbox:</strong> New therapies include <span class="ca-gterm" data-term="Bempedoic Acid">bempedoic acid</span>, <span class="ca-gterm" data-term="Evinacumab">evinacumab</span>, <span class="ca-gterm" data-term="Inclisiran">inclisiran</span>, and high-dose <span class="ca-gterm" data-term="Icosapent Ethyl">icosapent ethyl</span> — specifically not EPA+DHA mixtures.</li>

    <li><strong>ACS Management Shift:</strong> The outdated "stepwise" escalation approach is replaced by immediate <span class="ca-gterm" data-term="High-Intensity Statin">high-intensity statin</span> plus <span class="ca-gterm" data-term="Ezetimibe">ezetimibe</span> for most patients post-ACS.</li>

    <li><strong>Lp(a) Testing Standardized:</strong> Universal Lp(a) testing recommended at least once in adulthood, optimally with the first lipid profile. Lp(a) is positioned as a continuous, risk-enhancing factor.</li>

    <li><strong>New Extreme Risk Category:</strong> Patients with recurrent ASCVD events despite intensive therapy now have dedicated recognition and treatment guidance.</li>
  </ul>

  <h3>The Implementation Gap: JACC Stats 2026</h3>

  <p>Following the release of the 2025 ESC/EAS Focused Update, the inaugural <a href="https://www.jacc.org/doi/10.1016/j.jacc.2025.12.027" target="_blank" rel="noopener">JACC Cardiovascular Statistics 2026</a> (<a href="https://pubmed.ncbi.nlm.nih.gov/41524687/" target="_blank" rel="noopener">Wadhera et al.</a>) report delivered a sobering reality check. Despite therapeutic advances — <span class="ca-gterm" data-term="PCSK9 Gene">PCSK9</span> inhibitors, inclisiran, bempedoic acid, ezetimibe — population-level cardiovascular health has <strong>stalled or reversed</strong>:</p>

  <ul>
    <li><strong>LDL-C targets:</strong> Most high-risk patients still fail to reach guideline-recommended LDL-C goals</li>
    <li><strong>Statins underused:</strong> Even among patients with established ASCVD, statin prescribing and adherence remain suboptimal</li>
    <li><strong>Young adult MI rising:</strong> After years of decline (2004–2010), MI hospitalizations in young adults are increasing again — driven by obesity, diabetes, and <span class="ca-gterm" data-term="Metabolic Syndrome">metabolic syndrome</span></li>
    <li><strong>Obesity epidemic:</strong> Now affects >40% of U.S. adults, up from 34.5% in 2011–2012</li>
  </ul>

  <div class="ca-callout"><strong>Long-Acting Lipid Therapies — A Game-Changer?</strong> At a recent UTHealth Houston symposium, experts outlined how <strong>twice-yearly injectable medications</strong> could fundamentally reshape lipid management. Long-acting PCSK9 inhibitors and <span class="ca-gterm" data-term="Small Interfering RNA">siRNA</span>-based therapies (like <a href="https://www.novartis.com/us-en/news/media-releases/novartis-twice-yearly-leqvio-inclisiran-receives-fda-approval-new-indication-enabling-first-line-use" target="_blank" rel="noopener">inclisiran</a>) reduce LDL-C with just 1–2 injections per year, removing the daily adherence burden that undermines statin therapy. If these agents reach scale, lifetime cholesterol burden — and with it, lifetime ASCVD risk — could be dramatically reduced.</div>

  <!-- QUESTIONS FOR YOUR CARE TEAM -->
    <h2>2026 ACC/AHA/NLA Dyslipidemia Guidelines: The Landscape Shifts</h2>

  <p>On March 13, 2026, the ACC/AHA published the landmark <strong>2026 Guideline on the Management of Dyslipidemia</strong> (Blumenthal RS, et al., JACC 2026 — <a href="https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016" target="_blank" rel="noopener">JACC link</a>, also published in <a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423" target="_blank" rel="noopener">Circulation</a>). This 102-page document retires and replaces the 2018 Blood Cholesterol guidelines and represents the most comprehensive U.S. lipid guideline ever published. Even the name change tells the story — this is no longer just about cholesterol. It's about dyslipidemia in all its forms.</p>

  <h3>PREVENT-ASCVD: A New Risk Calculator</h3>

  <p>The Pooled Cohort Equations (PCE) have been replaced by the <strong>PREVENT-ASCVD equations</strong> (COR 1, LOE B-NR). PREVENT was derived from approximately 3.3 million contemporary U.S. adults (versus ~25,000 for PCE). PREVENT estimates are 40-50% lower than PCE for the same risk profile. New thresholds: Low <3%, Borderline 3-<5%, Intermediate 5-<10%, High ≥10%. Race/ethnicity is NOT a variable (it is a social construct, not a biologic predictor). PREVENT also provides 30-year risk estimation and <span class="ca-gterm" data-term="Heart Failure">heart failure</span> prediction. Optional inputs include HbA1c, albumin/<span class="ca-gterm" data-term="Creatinine">creatinine</span> ratio, and zip code for social deprivation index.</p>

  <div class="ca-callout"><strong>Important Note:</strong> Josh Wageman and other CAC advocates have critiqued PREVENT, noting that in validation studies 51% of patients PREVENT classified as "low risk" had CAC scores >0. This underscores why the guidelines pair PREVENT with the <span class="ca-gterm" data-term="CPR Framework">CPR framework</span> — the calculator is the starting point, not the final answer.</div>

  <h3>CPR Framework: Calculate-Personalize-Reclassify</h3>

  <p>The 2026 guidelines introduce a formal 3-step framework (Figure 5 in the guideline):</p>
  <ul>
    <li><strong>Calculate:</strong> Use PREVENT-ASCVD for 10-year and 30-year risk</li>
    <li><strong>Personalize:</strong> Discuss risk with patient, evaluate risk enhancers (family history, ethnicity, Lp(a), <span class="ca-gterm" data-term="C-Reactive Protein">hsCRP</span>, metabolic syndrome, albuminuria, etc.). The 2026 guideline formally adds <strong>reproductive risk markers</strong> to this list for the first time — adverse pregnancy outcomes (preeclampsia, gestational diabetes, preterm delivery), premature or early menopause, and polycystic ovary/metabolic syndrome (PCOS/PMOS) are now recognized risk-enhancing factors for personalized ASCVD risk assessment.</li>
    <li><strong>Reclassify:</strong> If uncertainty remains after shared decision-making, use coronary artery calcium (CAC) scoring to reclassify risk</li>
  </ul>

  <p>This is a memorable, structured approach that gives clinicians a clear pathway. CPR — it saves lives in more ways than one.</p>

  <h3>Absolute Treatment Goals Are Back</h3>

  <p>After 13 years of "percentage reduction only" in U.S. guidelines, concrete LDL-C and non-HDL-C number goals have returned. This is a massive shift. The 2026 guidelines now align U.S. recommendations closely with the ESC approach for the first time:</p>

  <table>
    <thead>
      <tr>
        <th>Risk Category</th>
        <th>LDL-C Goal</th>
        <th>Non-HDL-C Goal</th>
        <th>Optional ApoB Goal</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td><strong>Secondary Prevention (Very High Risk)</strong></td>
        <td><55 mg/dL</td>
        <td><85 mg/dL</td>
        <td><55 mg/dL</td>
      </tr>
      <tr>
        <td><strong>Secondary Prevention (Not Very High Risk)</strong></td>
        <td><70 mg/dL</td>
        <td><100 mg/dL</td>
        <td><70 mg/dL</td>
      </tr>
      <tr>
        <td><strong>Primary Prevention High Risk (≥10%)</strong></td>
        <td><70 mg/dL</td>
        <td><100 mg/dL</td>
        <td>—</td>
      </tr>
      <tr>
        <td><strong>Primary Prevention Borderline/Intermediate</strong></td>
        <td><100 mg/dL</td>
        <td><130 mg/dL</td>
        <td>—</td>
      </tr>
    </tbody>
  </table>

  <p><strong>Note:</strong> CardioAdvocate has long advocated for absolute goals. The return of specific LDL-C and non-HDL-C targets validates this position, and the transatlantic consensus is now here.</p>

  <h3>Universal Lp(a) Screening: COR 1</h3>

  <p>For the first time, a major U.S. guideline recommends measuring Lp(a) at least once in <strong>all adults</strong> (COR 1, LOE B-NR). Elevated Lp(a) is defined as ≥125 nmol/L (or ≥50 mg/dL). Very high Lp(a) is ≥200 nmol/L (≥75 mg/dL). In patients with ASCVD and elevated Lp(a) not at goal, PCSK9 mAbs are specifically recommended (COR 1, LOE B-R). This is a sea change from 2018 when Lp(a) was merely a "<span class="ca-gterm" data-term="Risk Enhancer">risk enhancer</span>" with no formal testing recommendation.</p>

  <h3>ApoB Gets a Seat at the Table</h3>

  <p>ApoB measurement is now COR 2a for adults on lipid-lowering therapy with ASCVD, metabolic dysfunction, diabetes, or elevated triglycerides. Optional ApoB goals: <55, <70, or <90 mg/dL depending on risk category. Non-HDL-C and ApoB are formally recognized as better than LDL-C alone for assessing atherogenic risk in hypertriglyceridemia.</p>

  <h3>New Drugs in the Arsenal</h3>

  <p>Five new FDA-approved therapies since 2018:</p>
  <ul>
    <li><strong>Bempedoic acid (COR 2a)</strong> — Oral <span class="ca-gterm" data-term="ACL Inhibitor">ACL inhibitor</span>, now approved in both primary AND secondary prevention. The CLEAR Outcomes trial demonstrated benefit. Available as combination pill with ezetimibe (Nexlizet).</li>
    <li><strong>Inclisiran (COR 2a)</strong> — siRNA targeting PCSK9, dosed every 6 months. Positioned as second-line PCSK9 inhibition (after mAbs) because <span class="ca-gterm" data-term="CVOT">CVOT</span> results (ORION 4, VICTORION-2 PREVENT) still pending. <em>Watch for VICTORION-CHALLENGE</em>, a Phase IV head-to-head trial of inclisiran vs. bempedoic acid for LDL-C goal achievement in high/very-high-risk ASCVD patients on maximally tolerated statins — the first direct comparison of these two non-statin options — presenting as a Late-Breaker at ESC Congress 2026 (Aug 31).</li>
    <li><strong>Evinacumab (COR 2b)</strong> — <span class="ca-gterm" data-term="ANGPTL3 Inhibitor">ANGPTL3 inhibitor</span> for homozygous familial hypercholesterolemia, works independently of LDL receptors.</li>
    <li><strong><span class="ca-gterm" data-term="Olezarsen">Olezarsen</span> (Tryngolza; COR 1, LOE B-R)</strong> — <span class="ca-gterm" data-term="Apolipoprotein C-III">ApoC-III</span> inhibitor. Originally approved for <span class="ca-gterm" data-term="Familial Chylomicronemia Syndrome">familial chylomicronemia syndrome</span>; <strong>FDA-approved June 30, 2026</strong> for the broader population of adults with severe hypertriglyceridemia (TG ≥500 mg/dL) to reduce triglycerides and risk of acute pancreatitis — the first agent approved specifically for pancreatitis risk reduction in sHTG. Monthly subcutaneous injection. CORE/CORE2 trials: 49–72% TG reduction at 6–12 months.</li>
    <li><strong>Evolocumab in primary prevention</strong> — <span class="ca-gterm" data-term="VESALIUS-CV">VESALIUS-CV</span> trial demonstrated 25% reduction in first cardiovascular events.</li>
    <li><strong>Enlicitide (Lipfendra; FDA-approved July 17, 2026)</strong> — The first oral PCSK9 inhibitor, a once-daily 20 mg tablet. The CORALreef Lipids and CORALreef HeFH trials (3,207 patients) showed 56–59% placebo-adjusted LDL-C reduction at 24 weeks — matching injectable PCSK9 inhibitors — with a safety profile essentially indistinguishable from placebo. Approved for LDL lowering; the CORALreef Outcomes trial (n>14,500) will determine whether this translates to reduced cardiovascular events. A pooled analysis presented at ASN Kidney Week 2026 found LDL-C lowering was preserved in patients with an eGFR below 60 (about 64–66% placebo-adjusted reduction), with no kidney dose adjustment needed. A second oral candidate, <strong>AZD0780</strong>, is advancing through Phase 3 development with a similar early efficacy signal on LDL-C, ApoB, and Lp(a).</li>
    <li><strong>Lerodalcibep (FDA-approved December 2025)</strong> — Third-generation injectable PCSK9 inhibitor, dosed monthly via a small-volume subcutaneous injection — less frequent than evolocumab/alirocumab (biweekly) and a practical option for patients struggling with injection frequency. Updated data presented at the 2026 European Atherosclerosis Society meeting showed a sustained 52% LDL-C reduction through 124 weeks, with a 28.7% reduction in Lp(a) and excellent tolerability.</li>
  </ul>

  <p><strong>Important:</strong> The 2026 guidelines no longer require ezetimibe before PCSK9 mAb. Drug selection is now based on degree of LDL-C lowering needed and patient preference/convenience. If a patient needs a 60% LDL-C reduction, you can go straight to a PCSK9 mAb. This is a game-changer for getting high-risk patients to goal faster.</p>

  <h3>VESALIUS-CV: PCSK9 Inhibitors Proven in Primary Prevention</h3>

  <p>A landmark development: <strong>VESALIUS-CV</strong> (Amgen, presented AHA 2025) enrolled 12,257 high-risk patients WITHOUT prior MI or <span class="ca-gterm" data-term="Stroke">stroke</span> on maximally tolerated statins. Evolocumab reduced <span class="ca-gterm" data-term="MACE">MACE</span> by 25% (HR 0.75, 95% CI 0.65-0.86) over 4.6 years, achieving median LDL-C ~45 mg/dL. This is the first PCSK9 inhibitor trial to show benefit in primary prevention, bridging the gap between <span class="ca-gterm" data-term="FOURIER Trial">FOURIER</span> (secondary prevention) and the new guideline recommendation to treat high-risk primary prevention patients aggressively. (<a href="https://www.acc.org/Latest-in-Cardiology/Articles/2025/11/03/16/19/sat-1010am-vesalius-aha-2025" target="_blank" rel="noopener">ACC Coverage of VESALIUS-CV</a>)</p>

  <h3>Supplements Formally Rejected: COR 3 No Benefit</h3>

  <p>For the first time, a major U.S. lipid guideline says <strong>do not use dietary supplements</strong> for LDL-C or triglyceride lowering. The <span class="ca-gterm" data-term="SPORT Trial">SPORT trial</span> showed rosuvastatin 5 mg beat ALL six tested supplements (fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice). CoQ10 also received COR 3: No Benefit for treating or preventing statin-attributed muscle symptoms.</p>

  <h3>CAC Scoring: From Tiebreaker to Centerpiece</h3>

  <p>The 2026 guidelines provide the most detailed CAC guidance ever in a U.S. guideline. Specific CAU-based tiered recommendations:</p>
  <ul>
    <li><strong>CAC = 0:</strong> Reasonable to defer lipid-lowering therapy (exceptions: FH, diabetes, smoking, strong family history)</li>
    <li><strong>CAC 1-99, <75th percentile:</strong> Moderate-intensity statin, goal LDL-C <100</li>
    <li><strong>CAC ≥100 or ≥75th percentile:</strong> Start lipid-lowering therapy, goal LDL-C <70</li>
    <li><strong>CAC 300-999:</strong> Goal LDL-C <70, non-HDL-C <100</li>
    <li><strong>CAC ≥1000:</strong> Treat like secondary prevention — goal LDL-C <55, non-HDL-C <85</li>
    <li><strong>Incidental CAC on noncardiac CT:</strong> COR 1 — should be considered in treatment decisions</li>
  </ul>

  <h3>Special Populations — New Firsts</h3>

  <p>Brief summary of guideline updates for special populations:</p>
  <ul>
    <li><strong>HIV:</strong> First-ever COR 1 for statin therapy based on REPRIEVE trial (pitavastatin 4 mg showed 35% MACE reduction)</li>
    <li><strong>CKD Stage 3+:</strong> Dedicated recommendations — moderate-intensity statin + ezetimibe (COR 1)</li>
    <li><strong>Pregnancy:</strong> Nuanced approach — very high risk FH/ASCVD patients may continue statins (COR 2b); previously a blanket "stop all statins"</li>
    <li><strong><span class="ca-gterm" data-term="Heart Failure with Reduced Ejection Fraction">HFrEF</span> without ASCVD:</strong> Upgraded to COR 3: No Benefit (from COR 2b in 2018) — CORONA, GISSI-HF trials demonstrated no benefit</li>
  </ul>

  <h2>Questions to Ask Your Care Team</h2>

  <ul>
    <li><strong>Is my clinician using the 2026 PREVENT calculator or the older Pooled Cohort Equations?</strong> The risk categories have changed with the new 2026 guidelines.</li>
    <li><strong>What is my LDL-C goal number?</strong> The 2026 guidelines restored specific targets — I should know mine.</li>
    <li><strong>Should I get a coronary artery calcium scan?</strong> The 2026 guidelines now have specific treatment recommendations based on CAC score thresholds.</li>
    <li><strong>Has my Lp(a) been checked?</strong> The 2026 guidelines recommend universal screening at least once in every adult's lifetime.</li>
    <li><strong>What is my ApoB level?</strong> The 2026 guidelines now formally recommend ApoB measurement for certain high-risk patients on lipid-lowering therapy.</li>
    <li><strong>I had a heart attack — should I be on combination therapy now rather than waiting to see if statins alone work?</strong></li>
    <li><strong>Are you considering my risk based on multiple guidelines</strong>, including the 2026 ACC/AHA approach?</li>
    <li><strong>Are there lipid medications I should avoid due to potential side effects?</strong></li>
    <li><strong>Should I be monitoring my liver enzymes or muscle symptoms while on lipid-lowering therapy?</strong></li>
    <li><strong>How often should my lipid levels be checked and what follow-up plan do we have?</strong></li>
  </ul>

  <h2>ACC 2026: The RCT Evidence Arrives</h2>

  <p>The 2026 ACC/AHA guidelines represent a watershed moment: for the first time in the intensive lipid-lowering era, we have dedicated <span class="ca-gterm" data-term="Randomized Controlled Trial">RCT</span> evidence proving that lower <span class="ca-gterm" data-term="LDL-C">LDL-C</span> targets produce better outcomes. Three landmark trials presented at ACC 2026 reinforce the aggressive lipid management strategy CardioAdvocate has championed.</p>

  <h3>Ez-PAVE Trial (NEJM 2026): The Proof Is Here</h3>

  <p><strong>Ez-PAVE</strong> is the first randomized controlled trial <strong>designed specifically</strong> to test whether an LDL-C target of <strong><55 mg/dL is superior to <70 mg/dL</strong>. Researchers enrolled 3,048 patients with established ASCVD and randomized them to intensive LDL-C lowering (<55 mg/dL) versus conventional targets (<70 mg/dL). Over 3 years of follow-up, intensive LDL-C lowering produced a <strong>33% reduction in MACE</strong> (major adverse cardiovascular events) compared to conventional targets — with <strong>identical safety profiles</strong> between groups.</p>

  <p>This trial answers a question that has shadowed lipid medicine for decades: Is there a cost to going lower? The answer is unequivocally no. The safety data — liver enzymes, muscle symptoms, new-onset diabetes, cognitive outcomes — showed no meaningful differences. Every mg/dL of additional LDL-C reduction translated to better cardiovascular outcomes, validating the principle that <strong>lower is better when it comes to LDL-C</strong>, and supporting the new ACC/AHA and ESC targets with robust randomized evidence.</p>

  <p><strong>The Bottom Line:</strong> Ez-PAVE closes the loop. The 2026 ACC/AHA LDL-C goal of <55 mg/dL for very high-risk patients is no longer based on observational data and biological plausibility alone — it's backed by a dedicated RCT showing clinical benefit with no safety signal. The debate is over.</p>

  <h3>VESALIUS-CV Diabetes Subgroup: PCSK9 Inhibitors Save Primary Prevention Diabetics</h3>

  <p>VESALIUS-CV, presented at ACC 2026, included a pre-specified diabetes subgroup analysis with powerful results: In high-risk diabetic patients <strong>without prior MI or stroke</strong>, evolocumab reduced the primary endpoint by <strong>31% (HR 0.69, P=0.009)</strong>. This strengthens an important case: <strong>PCSK9 inhibitors work upstream</strong>. High-risk diabetics in primary prevention benefit from intensive PCSK9-based lipid lowering — not just those with established ASCVD.</p>

  <p>This finding supports the 2026 guideline recommendation to use PCSK9 inhibitors in high-risk primary prevention populations, with special emphasis on diabetic patients whose competing vascular risk factors often go undertreated. The traditional paradigm — "save PCSK9 inhibitors for patients who've already had events" — is increasingly untenable.</p>

  <h3>ESSENCE-TIMI 73b CTA Substudy: Imaging Windows into Triglyceride Reduction</h3>

  <p>Also presented at ACC 2026, the coronary artery <span class="ca-gterm" data-term="CTA">CTA</span> substudy of ESSENCE-TIMI 73b examined the effects of <strong>olezarsen</strong>, an <span class="ca-gterm" data-term="Apolipoprotein C-III">apoC-III</span> inhibitor, on noncalcified plaque changes. The results underscore olezarsen's potency: patients achieved <strong>58–61% triglyceride reduction</strong> with olezarsen versus placebo, and <strong>85–89% reached normal triglyceride levels (<150 mg/dL)</strong>. These data support the 2026 guideline upgrade of olezarsen to COR 1 for familial chylomicronemia syndrome and suggest potential future roles in hypertriglyceridemia management.</p>

  <!-- THE BOTTOM LINE -->
  <div class="ca-summary-box">
    <h3>The Bottom Line</h3>

    <p>Guidelines keep improving. But as Ray and Kronenberg point out, without a fundamental change in how we implement evidence, we risk repeating the Sisyphean cycle — rolling the boulder up the hill only to watch it roll back down. CardioAdvocate exists to help close that gap.</p>

    <p>The 2013 ACC/AHA guidelines represented a well-intentioned but ultimately flawed interpretation of what "<span class="ca-gterm" data-term="Evidence-Based Medicine">evidence-based medicine</span>" should be. By restricting themselves to RCT data alone, guideline writers inadvertently created a situation where patients were potentially undertreated.</p>

    <p>Fortunately, the broader medical community — including ESC/EAS, <span class="ca-gterm" data-term="American Academy of Clinical Endocrinologists">AACE</span>/ACE, NLA, and other stakeholders — continued to provide more aggressive recommendations grounded in clinical expertise and a broader interpretation of the evidence base.</p>

    <p>The path forward requires:</p>
    <ul>
      <li>Patient-centered care informed by multiple guidelines</li>
      <li>Recognition that guidelines are starting points, not endpoints</li>
      <li>Access to specialist input when patients fall outside standard categories</li>
      <li>Regular monitoring and reassessment of lipid levels</li>
      <li>Aggressive treatment of highest-risk patients, not complacency</li>
    </ul>

    <p>Don't accept undertreatment simply because you're "following the guidelines." Ask your care team which guidelines they're using, why they chose those guidelines, and whether your individual circumstances warrant a more aggressive approach. The guidelines are there to guide you — not to limit you.</p>

    <p style="margin-top: 15px; padding-top: 15px; border-top: 1px solid #2E8B8B;"><strong>February 2026 Update:</strong> The inaugural <a href="https://www.jacc.org/doi/10.1016/j.jacc.2025.12.027" target="_blank" rel="noopener">JACC Cardiovascular Statistics 2026</a> (<a href="https://pubmed.ncbi.nlm.nih.gov/41524687/" target="_blank" rel="noopener">Wadhera et al., PubMed</a>) report confirms the implementation gap remains the real crisis — most high-risk patients still fail to reach LDL-C targets, statins remain underused, and young adult MI hospitalizations are rising. Meanwhile, innovation continues: <strong>twice-yearly injectable lipid-lowering therapies</strong> (including long-acting PCSK9 inhibitors and siRNA agents like inclisiran) could dramatically reduce lifetime cholesterol burden and solve the adherence problem that undermines even the best guidelines. The question is no longer whether we have the tools — it's whether we use them.</p>

    <p><strong>March 2026 Update:</strong> The 2026 ACC/AHA/NLA Dyslipidemia Guidelines represent the most significant shift in U.S. lipid management in over a decade. PREVENT replaces the Pooled Cohort Equations. Absolute LDL-C and non-HDL-C goals are back. Universal Lp(a) screening is now Class I. Five new drugs have entered the algorithm. Supplements are formally rejected. And CAC scoring has evolved from a tiebreaker to a clinical decision-making centerpiece. After years of the U.S. lagging behind European guidelines, the gap has narrowed dramatically. CardioAdvocate's position — treat aggressively, measure comprehensively, and never accept therapeutic inertia — has never been more aligned with mainstream guidance.</p>

    <p><strong>October 2026 Update — The Gap Is Treatment, Not Targets.</strong> <a href="https://www.tctmd.com/news/researchers-offer-preview-2026-dyslipidemia-guidelines-impact" target="_blank" rel="noopener">Companion JAMA analyses</a> applying the 2026 guideline to national data estimate that about 80% of adults with established ASCVD are above their LDL-C goal, and among them roughly 38% are on no lipid-lowering therapy. In primary prevention, about 32% of adults exceed their goal, and switching from the pooled cohort equations to PREVENT reclassified about 21.5% of adults while leaving overall statin recommendation rates near 49%. These are population-level estimates; the practical message is to check every patient’s LDL-C against the new goal rather than assume therapy is adequate.</p>
  </div>

  <div class="ca-tagline">
    CardioAdvocate helps people understand what matters — and how to speak up about it.
  </div>

  
  <!-- FOOT STOMPERS -->
  <h2>Foot Stompers: Key Takeaways</h2>

  <div class="fl-foot-stomper">
    <div class="fl-foot-stomper-title">Guidelines lag behind science</div>
    <div class="fl-foot-stomper-text">By the time a guideline committee convenes, debates, and publishes, the evidence has often moved on; the best clinicians treat to the latest evidence, not just the latest guideline.</div>
  </div>

  <div class="fl-foot-stomper">
    <div class="fl-foot-stomper-title">Ez-PAVE: The RCT proof that lower LDL-C is better</div>
    <div class="fl-foot-stomper-text">Ez-PAVE is the first randomized trial proving that targeting LDL-C <55 mg/dL produces better outcomes than <70 mg/dL — with identical safety. The debate is over. Every mg/dL counts.</div>
  </div>

  <div class="fl-foot-stomper">
    <div class="fl-foot-stomper-title">LDL-C below 55 mg/dL for very high risk</div>
    <div class="fl-foot-stomper-text">Both ESC and now the 2026 ACC/AHA guidelines agree — if you've had an ASCVD event with very high risk features, your LDL-C target is below 55 mg/dL. Ez-PAVE provides RCT confirmation. The transatlantic consensus is here.</div>
  </div>

  <div class="fl-foot-stomper">
    <div class="fl-foot-stomper-title">ApoB is the better metric</div>
    <div class="fl-foot-stomper-text">Every major guideline society now acknowledges ApoB's superiority to LDL-C alone, yet most doctors still don't order it; ask for yours.</div>
  </div>

  <div class="fl-foot-stomper">
    <div class="fl-foot-stomper-title">Therapeutic inertia kills</div>
    <div class="fl-foot-stomper-text">Studies show the majority of high-risk patients never reach their lipid targets; it's not that we lack the drugs, it's that we fail to intensify therapy.</div>
  </div>

  <div class="fl-foot-stomper">
    <div class="fl-foot-stomper-title">PREVENT risk calculator + CAC = the new dynamic duo</div>
    <div class="fl-foot-stomper-text">PREVENT gets you in the ballpark, but CAC scoring tells you who's really at risk. In validation studies, 51% of PREVENT 'low-risk' patients had coronary calcium. Never stop at the calculator.</div>
  </div>

  <div class="fl-foot-stomper">
    <div class="fl-foot-stomper-title">Lp(a) screening is now Class I</div>
    <div class="fl-foot-stomper-text">Every adult should have their Lp(a) checked at least once. Period. It's genetic, it's common (1 in 5 people have elevated levels), and there's nothing you can do about it with diet or exercise — but you CAN manage the risk if you know about it.</div>
  </div>

  <div class="fl-foot-stomper">
    <div class="fl-foot-stomper-title">VESALIUS-CV changes primary prevention</div>
    <div class="fl-foot-stomper-text">Evolocumab reduced first cardiovascular events by 25% in high-risk patients who had never had a heart attack or stroke. PCSK9 inhibitors are no longer just for secondary prevention — they're proven upstream too.</div>
  </div>

  <!-- REFERENCE SECTION -->
  <h2>References</h2>

  <h3>Key ACC 2026 Trials</h3>
  <ul>
    <li><strong>Ez-PAVE Trial (NEJM 2026):</strong> First randomized controlled trial demonstrating that LDL-C <55 mg/dL is superior to <70 mg/dL in ASCVD patients, with 33% MACE reduction and identical safety profiles. (To be published in <em>New England Journal of Medicine</em>, 2026)</li>
    <li><strong>VESALIUS-CV Diabetes Subgroup (ACC 2026):</strong> Evolocumab reduced primary endpoint by 31% (HR 0.69, P=0.009) in high-risk diabetic patients without prior MI/stroke, demonstrating PCSK9 inhibitor benefit in primary prevention. Presented at American College of Cardiology Scientific Sessions, 2026.</li>
    <li><strong>ESSENCE-TIMI 73b CTA Substudy (ACC 2026):</strong> Olezarsen achieved 58–61% triglyceride reduction and 85–89% attainment of normal TG levels (<150 mg/dL) in coronary imaging analysis. Presented at American College of Cardiology Scientific Sessions, 2026.</li>
  </ul>

  <h3>Historical and Landmark References</h3>
  <ul>
    <li>Ray KK, Kronenberg F. "Seventeen Years to Change Practice: Will the 2025 ESC/EAS Dyslipidaemia Guidelines Finally Break the Sisyphean Cycle?" <em>Atherosclerosis</em> 2026;120636.</li>
  </ul>

  <!-- RECOMMENDED RESOURCES -->
  <h2>Recommended Resources</h2>

  <h3>Guidelines and Position Statements</h3>
  <ul>
    <li><a href="https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016" target="_blank" rel="noopener">2026 ACC/AHA/NLA Guideline on the Management of Dyslipidemia (JACC)</a></li>
    <li><a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423" target="_blank" rel="noopener">2026 ACC/AHA/NLA Guideline on the Management of Dyslipidemia (Circulation)</a></li>
    <li><a href="https://academic.oup.com/eurheartj/article/41/1/111/5556353" target="_blank" rel="noopener">2019 ESC/EAS Guidelines for the management of dyslipidaemias</a></li>
    <li><a href="https://academic.oup.com/eurheartj/article/46/42/4359/8234482" target="_blank" rel="noopener">2025 ESC/EAS Focused Update on dyslipidaemia management</a></li>
    <li><a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000624" target="_blank" rel="noopener">2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol</a></li>
    <li><a href="https://www.endocrinepractice.org/article/S1530-891X(20)30642-9/fulltext" target="_blank" rel="noopener">AACE/ACE Consensus Statement on the Management of Dyslipidemia — 2020</a></li>
    <li><a href="https://www.lipidjournal.com/article/S1933-2874(14)00274-8/fulltext" target="_blank" rel="noopener">2014 National Lipid Association Management of Dyslipidemia Guidelines</a></li>
    <li><a href="https://www.nhlbi.nih.gov/files/docs/resources/heart/atp-3-cholesterol-full-report.pdf" target="_blank" rel="noopener">2004 ATP III Report on High Blood Cholesterol (Historical Reference)</a></li>
  </ul>

  <h3>Risk Assessment Tools</h3>
  <ul>
    <li><a href="https://professional.heart.org/en/guidelines-and-statements/prevent-calculator" target="_blank" rel="noopener">PREVENT-ASCVD Calculator (AHA)</a> — 10-year and 30-year risk estimation (2026)</li>
    <li><a href="https://shareddecisions.mayoclinic.org/statindecisionaid/" target="_blank" rel="noopener">Mayo Clinic Statin Choice Decision Aid</a> — Multiple risk calculators including ACC/AHA PCE, Reynolds, Framingham</li>
    <li><a href="https://www.heartscore.org/en_GB/" target="_blank" rel="noopener">European HeartScore</a> — Risk prediction tool for European populations</li>
    <li><a href="https://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/SCORE-Risk-Charts" target="_blank" rel="noopener">SCORE2 and SCORE2-OP</a> — Updated risk assessment (2025 ESC/EAS)</li>
  </ul>

  <h3>Specialist Resources</h3>
  <ul>
    <li><a href="https://www.learnyourlipids.com/find-a-clinician/" target="_blank" rel="noopener">LearnYourLipids</a> — Find a cardiometabolic specialist or lipidologist</li>
    <li><a href="https://x.com/JohnKastelein" target="_blank" rel="noopener">Expert Thought Leaders: John Kastelein (@JohnKastelein) on X</a></li>
    <li><a href="https://x.com/Drlipid" target="_blank" rel="noopener">Expert Thought Leaders: Thomas Dayspring (@Drlipid) on X</a></li>
  </ul>

  <h3>Related CardioAdvocate Content</h3>
  <ul>
    <li><a href="https://cardioadvocate.com/phenotypes/heart-attack-survivor" target="_blank" rel="noopener">The Repeat Offender (The Heart Attack Survivor)</a> — Secondary prevention and aggressive lipid lowering</li>
    <li><a href="https://cardioadvocate.com/phenotypes/familial-hypercholesterolemia" target="_blank" rel="noopener">Hiding in Plain Sight: Familial Hypercholesterolemia</a></li>
    <li><a href="https://cardioadvocate.com/phenotypes/coronary-artery-calcium-scores" target="_blank" rel="noopener">A Picture is Worth a Thousand Words: Coronary Artery Calcium Scores</a></li>
    <li><a href="https://cardioadvocate.com/phenotypes/lipoprotein-a-lpa" target="_blank" rel="noopener">Little Napoleon Complex: Lipoprotein (a)</a></li>
    <li><a href="https://cardioadvocate.com/phenotypes/atherogenic-triad" target="_blank" rel="noopener">Atherogenic Triad</a> — The dangerous lipid <span class="ca-gterm" data-term="Phenotype">phenotype</span> associated with <span class="ca-gterm" data-term="Visceral Adiposity">visceral adiposity</span></li>
  </ul>

  <div class="ca-closing-disclaimer">
    <strong>Disclaimer:</strong> This article is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare providers with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking treatment because of information in this article. CardioAdvocate.com does not endorse any specific treatment, medication, or procedure mentioned herein. Readers are responsible for independently verifying all information and consulting with appropriate healthcare professionals before making any medical decisions.
  </div>

</div>
Previous
Previous

Drinking Buddies: Atrial Fibrillation and Its Cardiometabolic Companions

Next
Next

Cheating Death: The Heart Attack Survivor